An NGS amplicon tiling protocol for HIV-1 drug resistance detection using Illumina® COVIDSeq™ Assay Kit.

Eugene Yeboah, Noah C. Hull, Vanda Makris, laura.j.tsaknaridis

Published: 2023-12-04 DOI: 10.17504/protocols.io.n92ldmq4ol5b/v1

Abstract

Summary

Human immunodeficiency virus (HIV) is the pathogen responsible for acquired immunodeficiency syndrome (AIDS) and continues to be a significant global public health issue. HIV can be managed with antiretroviral (ART) drug treatments by suppressing the viral replication of HIV within the infected individual. Unfortunately, due to the nature of the virus, drug resistance can occur, making the ART drug no longer effective. An amplicon-based assay, such as the Illumina COVIDSeqTM Assay (RUO), was adopted to sequence the entire genome of the HIV-1 virus. We modified the

Illumina COVIDSeTMM Assay (RUO) protocol to prepare HIV-1 libraries and sequenced on the Illumina MiSeq. The sequencing data was analyzed by Terra.bio and Exatype NGS. This study demonstrated the utility of the assay to efficiently

sequence near-complete genome of HIV-1 virus up to 488 viral copies and provide accurate information for drug resistance detection.    

Background

According to the World Health Organization, an estimated 39.0 million [33.1–45.7 million] people live with HIV at the end of 2022 [1]. UNAIDS reported that 40.4 million [32.9 million–51.3 million] people have died from AIDS-related illnesses since the start of the epidemic [2]. HIV drug resistance testing is crucial for managing and preventing ARV failures for persons undergoing treatment or drug-naive individuals [3]. Traditionally, HIV drug resistance testing is performed by Sanger sequencing of specific regions within the HIV genome to identify drug resistance mutations. Next-generation sequencing (NGS) technologies have recently been implemented to improve sensitivity and reproducibility and reduce the cost per sample by multiplexing.

In this study, the Oregon State Public Health Laboratory (OSPHL), in collaboration with the Association of Public Health Laboratory (APHL), evaluated the performance of the Illumina COVIDSeqTMAssay (RUO) for HIV complete genome sequencing (HIVSeq). We describe a step-by-step HIV-1 virus genome sequencing protocol that leverages the Illumina COVIDSeqTM Assay (RUO), with reagents remaining the same.  The modified protocol utilizes HIV-1 primers designed through primal scheme. We demonstrate that whole genome sequencing of the HIV-1 virus can be achieved with extensive sequencing coverage for viral copies up to 488. Thereby expanding the use of the Illumina COVIDSeqTMAssay (RUO)

beyond SARS-CoV-2.

Results

To evaluate the performance of the assay, HIV-1 strain: IIIB positive culture control from ZeptoMetrix (Part #v0801032CF) was extracted and serially diluted to the following concentration: 10ᶺ(-1), 10ᶺ(-2), 10ᶺ(-3), 10ᶺ(-4), 10ᶺ(-5), and 10ᶺ(-6). Library preparation of the diluted viral nucleic extracts was sequenced on the Illumina MiSeq 2 x 150 bp. Viral copies ranged from 48.8 to 4,880,000 viral RNA copies/ul. We evaluated the assay's performance for accuracy, precision,

sensitivity, specificity, and limit of detection.

HIV-1 primers s

designed with Primal Scheme: Complete Primers under MATERIALS section.

To verify the coverage and detect drug-resistant mutations of all samples, we used FASTQ files exported from the MiSeq instrument. We uploaded them to the Terra platform, used the Illumina PE TheiaCov workflow developed by Theiagen, and mapped them to reference NC-001802.1 to generate run and quality metrics. FASTA files were analyzed for drug resistance mutations using Exatype NGS by Hyraxbio.  All samples were run in triplicates. Quality metrics and coverage analysis are shown in Tables 1A and 1B. The average percent reference coverage for viral loads of 4,880,000, 488,000,

48,800, 4,880, and 488 were >90%. Reference coverage for negative controls was undetected due to assembly failure. These results showed that the assay performed well in sequencing HIV-1-positive virus.

To evaluate the accuracy of the assay, we leveraged the HIV-1 positive control’s mutations. The positive control has a non-polymorphic mutation F227L found in the non-nucleoside reverse transcription. We calculated the percent accuracy based on the ability of the assay to identify this mutation in all 17 samples that passed quality control metrics. Table 2 shows a

100% consistent detection of the F227L mutation in all samples.

We evaluated the analytical sensitivity of the assay based on the HIV-1 positive control drug-resistant profile within the NRTI – Nucleoside Reverse Transcriptase Inhibitors (susceptible), NNRTI - Non-Nucleoside Reverse Transcriptase Inhibitors (3 intermediate and F227L mutation), PI - Protease Inhibitors (susceptible), and INSTI - Integrase Inhibitors regions (susceptible). The assay detected concordant results in 64 out of 68 drug classes and their resistance calls in all the dilution series (64/68) x 100 = 94%). Data is shown in table 4. Within-run precision was calculated based on three replicates from each dilution series (4.880,000, 488,000, 48,000, 4,800, 480, and 48.8 copies) of the HIV-1 subtype B positive control and three replicates of a negative template control. There were expected 17 positive and eight negative

(3 negative and five non-HIV specimens). The miscalculation rate was 0%. Also, Positive Predictive Value =100% and Negative Predictive Value = 100%. Figure 1 demonstrates that sequencing the HIV-1 genome using the COVIDSeTM Assay (RUO) (on the Illumina MiSeq 2X150) produces >80% coverage of the complete HIV-1 genome with viral copy down to 488 copies/ul. 

Analytical specificity and coinfection for HIV-1 genome were evaluated using confirmed positive samples of HAV-Hepatitis A, HBV-Hepatitis B, HCV-Hepatitis C, and two TP-Syphilis. All samples were confirmed to be negative for HIV-1. QC metrics failed for all five samples due to genome assembly failure and no reads, as depicted in Table 6.  Another evaluation of analytical specificity of the mutation detected was calculated based on the assay’s ability to detect the

mutation, F227C, a rare nonpolymorphic mutation at position 106, at NNRTI - Non-Nucleoside Reverse Transcriptase

Inhibitors region in each of the 17 samples at the different viral loads of (4.880,000, 488,000, 48,000, 4,800,

480, and 48.8). Table 5 shows (17/17) x 100 =100.00% analytical specificity to detect the mutation.

We evaluated the Limit of Detection by analyzing all samples, their experimental/expected results, and the ability to detect

mutations and drug-resistant calls in all four drug-resistant regions of the Pol Region (NRTI, NNRTI, PI, and INSTI). Table 6 shows a 100% concordance between expected and experimental results for

viral copy number dilutions up to 10ᶺ (-5) or 488 copies.

At 10ᶺ (-6) or 49 viral copies, sensitivity decreases to 8/12 = 67%.

These results in Table 7 indicate that positive HIV-1 samples with viral loads up to 488 copies can reliably produce a drug resistance profile. Viral copies under 488 have inconsistent results and do not pass quality control metrics.

*One sample from HIV_PC_1:10e4 (2) failed QC due to sample loss during library preparation.  Analysis shows inclusion and omission metrics. Triplicate Average: Average mean calculation for dilutions (all dilutions were run in triplicate)

Table 1B. HIV-1 Positive Control Quality Control Metrics (Raw Data) Analysis on Terra.bio

ABCDEF
Dilution FactorAssembly Length UnambiguousAssembly Mean CoverageNumber of  NsTotal Number% Reference Coverage
HIV_PC_10_190406854.19128917598.46
HIV_PC_10_290405455.84135918298.46
HIV_PC_10_3907911842.688917498.89
HIV_PC_100_190406085.74125917298.46
HIV_PC_100_290416447.61122916998.48
HIV_PC_100_390404327.41102914998.46
HIV_PC_1000_1904110369.2105915298.48
HIV_PC_1000_290404998.39121916898.46
HIV_PC_1000_390393504.9105915298.45
HIV_PC_10000_1904414738.5127917498.51
HIV_PC_10000_250108504.213419843254.57
HIV_PC_10000_387694044.16375915195.51
HIV_PC_100000_187395186.66399914295.19
HIV_PC_100000_287305353.17411915695.09
HIV_PC_100000_381293741.451014914988.54
HIV_PC_1000000_162632370.052879914768.22
HIV_PC_1000000_267842204.52361915173.89
HIV_PC_1000000_364412068.952713915670.16

*One sample from HIV_PC_1:10e4 [HIV_PC_10000_2] failed QC due to sample loss during library preparation.

Table 3. HIV Drug Resistance Mutations

HIV-1 drug-resistant profiles from Exatype NGS, using the Stamford HIV drug-resistant database.

ABCDE
Dilution FactorNRTI – Nucleoside Reverse Transcriptase InhibitorsNNRTI - Non-Nucleoside Reverse Transcriptase InhibitorsPI - Protease InhibitorsINSTI - Integrase Inhibitors
HIV_PC_10_1Susceptible2-Susceptible, 3-Intermediate ETR : [RT] F227LSusceptibleSusceptible
HIV_PC_10_2Susceptible2-Susceptible, 3-Intermediate ETR : [RT] F227LSusceptibleSusceptible
HIV_PC_10_3Susceptible2-Susceptible, 3-Intermediate ETR : [RT] F227LSusceptibleSusceptible
HIV_PC_100_1Susceptible2-Susceptible, 3-Intermediate ETR : [RT] F227LSusceptibleSusceptible
HIV_PC_100_2Susceptible2-Susceptible, 3-Intermediate ETR : [RT] F227LSusceptibleSusceptible
HIV_PC_100_3Susceptible2-Susceptible, 3-Intermediate ETR : [RT] F227LSusceptibleSusceptible
HIV_PC_1000_1Susceptible2-Susceptible, 3-Intermediate ETR : [RT] F227LSusceptibleSusceptible
HIV_PC_1000_2Susceptible2-Susceptible, 3-Intermediate ETR : [RT] F227LSusceptibleSusceptible
HIV_PC_1000_3Susceptible2-Susceptible, 3-Intermediate ETR : [RT] F227LSusceptibleSusceptible
HIV_PC_10000_1Susceptible2-Susceptible, 3-Intermediate ETR : [RT] F227LSusceptibleSusceptible
HIV_PC_10000_2Low coverageLow coverageLow coverageLow coverage
HIV_PC_10000_3Susceptible2-Susceptible, 3-Intermediate ETR : [RT] F227LSusceptibleSusceptible
HIV_PC_100000_1Susceptible2-Susceptible, 3-Intermediate ETR : [RT] F227LSusceptibleSusceptible
HIV_PC_100000_2Susceptible2-Susceptible, 3-Intermediate ETR : [RT] F227LSusceptibleSusceptible
HIV_PC_100000_3Susceptible2-Susceptible, 3-Intermediate ETR : [RT] F227LSusceptibleSusceptible
HIV_PC_1000000_1Susceptible2-Susceptible, 3-Intermediate ETR : [RT] F227LSusceptibleLow coverage
HIV_PC_1000000_2Susceptible2-Susceptible, 3-Intermediate ETR : [RT] F227LLow coverageLow coverage
HIV_PC_1000000_3Susceptible2-Susceptible, 3-Low coverage ETR : [RT] F227LSusceptibleLow coverage

*One sample from HIV_PC_1:10e4 [HIV_PC_10000_2] failed QC due to sample loss during library preparation.

Table 4: Within Run Precision ion

ABCDEF
SensitivityNumber of Copies n=6/dilutionNRTI – Nucleoside Reverse Transcriptase InhibitorsNNRTI - Non-Nucleoside Reverse Transcriptase InhibitorsPI - Protease InhibitorsINSTI - Integrase Inhibitors
8/12HIV_PC_10ᶺ(-6), _1Susceptible2-Susceptible, 3-Intermediate ETR : [RT] F227LSusceptibleLow coverage
HIV_PC_10ᶺ(-6), _2Susceptible2-Susceptible, 3-Intermediate ETR : [RT] F227LLow coverageLow coverageLow coverage
HIV_PC_10ᶺ(-6), _3Susceptible2-Susceptible, 3-Low coverage ETR : [RT] F227LSusceptibleLow coverageLow coverage
12/12HIV_PC_10ᶺ(-5), _1Susceptible2-Susceptible, 3-Intermediate ETR : [RT] F227LSusceptibleSusceptible
HIV_PC_10ᶺ(-5), _2Susceptible2-Susceptible, 3-Intermediate ETR : [RT] F227LSusceptibleSusceptibleSusceptible
HIV_PC_10ᶺ(-5), _3Susceptible2-Susceptible, 3-Intermediate ETR : [RT] F227LSusceptibleSusceptibleSusceptible
*8/12 8/8HIV_PC_10ᶺ(-4), _1Susceptible2-Susceptible, 3-Intermediate ETR : [RT] F227LSusceptibleSusceptible
HIV_PC_10ᶺ(-4), _2Low coverageLow coverageLow coverageLow coverageSusceptible
HIV_PC_10ᶺ(-4), _3Susceptible2-Susceptible, 3-Intermediate ETR : [RT] F227LSusceptibleSusceptibleSusceptible
12/12HIV_PC_10ᶺ(-3), _1Susceptible2-Susceptible, 3-Intermediate ETR : [RT] F227LSusceptibleSusceptible
HIV_PC_10ᶺ(-3), _2Susceptible2-Susceptible, 3-Intermediate ETR : [RT] F227LSusceptibleSusceptibleSusceptible
HIV_PC_10ᶺ(-3), _3Susceptible2-Susceptible, 3-Intermediate ETR : [RT] F227LSusceptibleSusceptibleSusceptible
12/12HIV_PC_10ᶺ(-2), _1Susceptible2-Susceptible, 3-Intermediate ETR : [RT] F227LSusceptibleSusceptible
HIV_PC_10ᶺ(-2), _2Susceptible2-Susceptible, 3-Intermediate ETR : [RT] F227LSusceptibleSusceptibleSusceptible
HIV_PC_10ᶺ(-2), _3Susceptible2-Susceptible, 3-Intermediate ETR : [RT] F227LSusceptibleSusceptibleSusceptible
12/12HIV_PC_10ᶺ(-1), _1Susceptible2-Susceptible, 3-Intermediate ETR : [RT] F227LSusceptibleSusceptible
HIV_PC_10ᶺ(-1), _2Susceptible2-Susceptible, 3-Intermediate ETR : [RT] F227LSusceptibleSusceptibleSusceptible
HIV_PC_10ᶺ(-1), _3Susceptible2-Susceptible, 3-Intermediate ETR : [RT] F227LSusceptibleSusceptibleSusceptible

(64/68) x 100 = 94% *(64/72) x 100 = 89% *One sample from HIV_PC_1:10e4 [HIV_PC_10000_2] failed QC due to sample loss during library preparation.

Table 5: : Analytical Specificity for Mutation Detected:

ABC
Analytical SpecificityNumber of Copies n=6/dilutionNNRTI - Non-Nucleoside Reverse Transcriptase Inhibitors
3/3HIV_PC_10ᶺ(-6)ETR : [RT] F227L
3/3HIV_PC_10ᶺ(-5)ETR : [RT] F227L
*2/3 2/2HIV_PC_10ᶺ(-4)ETR : [RT] F227L
Low coverage
ETR : [RT] F227L
3/3HIV_PC_10ᶺ(-3)ETR : [RT] F227L
3/3HIV_PC_10ᶺ(-2)ETR : [RT] F227L
3/3HIV_PC_10ᶺ(-1)ETR : [RT] F227L

(17/17) x 100 =100.00%*(17/18) x 100 = 94%*One sample from HIV_PC_1:10e4 (2) failed QC due to sample loss during library preparation.  Analysis shows inclusion and omission metrics.

Table 6 6: Analytical Specificity of Co-infection

ABC
Accession #SpecimenHIV-1 Assay Result
7427HAV+No sequence
1701HBV+No sequence
1740HCV+No sequence
4023TP+No sequence
7214TP+No sequence

Table 7: : Limit of Detection Threshold

ABCDEF
SensitivityNumber of Copies n=6/dilutionNRTI – Nucleoside Reverse Transcriptase InhibitorsNNRTI - Non-Nucleoside Reverse Transcriptase InhibitorsPI - Protease InhibitorsINSTI - Integrase Inhibitors
8/12HIV_PC_10ᶺ(-6), _1Susceptible2-Susceptible, 3-Intermediate ETR : [RT] F227LSusceptibleLow coverage
HIV_PC_10ᶺ(-6), _2Susceptible2-Susceptible, 3-Intermediate ETR : [RT] F227LLow coverageLow coverageLow coverage
HIV_PC_10ᶺ(-6), _3Susceptible2-Susceptible, 3-Low coverage ETR : [RT] F227LSusceptibleLow coverageLow coverage

At 10ᶺ (-6) or 49 viral copies, sensitivity decreases to 8/12 = 67%.

These results indicate that positive HIV-1 samples with viral loads up to 488 copies can reliably produce a drug resistance profile. However, viral copies under 488 have inconsistent results and do not pass quality control metrics.

Note:

It is important to note that the positive control was a culture of a USA HIV-1 strain IIIB, and primers used for this assay were designed based on HIV-1 sequences primarily from North America. Due to the high genome variability of

the HIV-1 virus, primers must be designed using sequences in or around the region of interest. The primers used in this assay performed well, with good genome coverage on samples from North America. However, they showed poor coverage of HIV-1-positive samples from different continents. Hence, the recommendation of designing primers specific to the region to account for variations within the region to achieve higher genome coverage References: ferences:

[1]“HIV World Health Organization rganization, World Health Organization, 13 July 2023, www.who.int/news-room/fact sheets/detail/hiv-aids.

[2]“Global HIV & AIDS Statistics — Www.unaids.org ww.unaids.org, 2023, www.unaids.org/en/resources/factsheet\#:\~:text=Global%20HIV%20statistics&text=29.8%20million%20people%20were%20accessing. Accessed 15 Oct. 2023.

[3] Günthard H.F., Calvez V., Paredes R., Pillay D., Shafer R.W., Wensing A.M., Jacobsen D.M., Richman D.D. Human

immunodeficiency virus drug resistance: 2018 recommendations of the international antiviral soc Clin. Infect. Dis. n. In 68 ct. Dis. 2019;68:177–187. doi: 10.1093/cIllumina COVIDSeq RUO Kits Reference Guide (1000000126053 v08)10 Illumina COVIDSeq Research Use Only Kits Documentation. KCOVIDSeq Assay (96 samples) | Low-throughput COVID-19 surveillance (illumina.com)ance

(illumina.com). 2022

Steps

1.

Sequencing libraries were prepared using reagents in the Illumina COVIDSeq Assay (RUO) kit with a protocol modified by substituting SARS-CoV-2 primers with HIV-1 primers.

2.

Sample Extraction

HIV-1 subtype B positive culture

control ZeptoMetrix (Part #v0801032CF), was extracted via the Qiagen Advanced XL DSP kit on the EZ1 extractor and serially diluted to the following concentration: 10ᶺ(-1), 10ᶺ(-2), 10ᶺ(-3), 10ᶺ(-4), 10ᶺ(-5), and 10ᶺ(-6), Undiluted control (1.7410^10 IU/mL or 2.0910^10 ng/ml); Sample was diluted 1:10 = 2.09*10^9 ng/ml before extraction. cDNA Synthesis and Amplification n

3.

Prepare the HIV-1 primer pool as described by the manufacturer. Individual primers were obtained from IDT as desalted, lab-ready stock at 100mM concentration. Dilute each primer at ratios provided by the manufacturer. Dilute the primer pool to get a 10 µM working concentration.

4.

Prepare the following consumables:

ABC
ReagentStorageInstructions
EPH3-25°C to -15°CThaw at room temperature, and then invert to mix

Save the following COVIDSeq Anneal program on the thermal cycler:

  • Choose the preheat lid option
  • Set the reaction volume to 17 µl
  • 65°C for 3 minutes
  • Hold at 4°C

Procedure

  1. Label new PCR plate CDNA1.
  2. Add 8.5 µl EPH3 to each well.
  3. Add 8.5 µl eluted sample to each well.
  4. Seal and shake at 1600 rpm for 1 minute.
  5. Centrifuge at 1000 × g for 1 minute.
  6. Place on the preprogrammed thermal cycler and run the COVIDSeq Anneal program.
5.

Synthesize First Strand cDNA:

ABC
ReagentStorageInstructions
RVT-25°C to -15°CInvert to mix before use. Keep on ice
FSM-25°C to -15°CThaw and bring to room temperature. Invert to mix, and then keep on ice.

Save the following COVIDSeq FSS program on the thermal cycler:

  • Choose the preheat lid optio.n
  • Set the reaction volume to 25 µl
  • 25°C for 5 minutes
  • 50°C for 10 minutes
  • 80°C for 5 minutes
  • Hold at 4°C

Procedure

  1. In a 1.7 ml tube, combine the following volumes to prepare First Strand cDNA Master Mix. Multiply each volume by the number of samples.
  • FSM (9 µl)
  • RVT (1 µl) Reagent overage is included to account for small pipetting errors.
  1. Add 8 µl master mix to each well of the CDNA1 plate.

  2. Seal and shake at 1600 rpm for 1 minute.

  3. Centrifuge at 1000 × g for 1 minute.

  4. Place on the preprogrammed thermal cycler and run the COVIDSeq FSS program

SAFE STOPPING POINT:   If you are stopping, seal the plate and store at -25°C to -15°C for up to 7 days.

6.

Amplify cDNA:

Preparation:

  1. Prepare the following consumables:
ABC
ReagentStorageInstructions
CPP1-25°C to -15°CThaw at room temperature. Keep on ice until use.
CPP2-25°C to -15°CThaw at room temperature. Keep on ice until use.
IPM-25°C to -15°CThaw at room temperature, and then invert to mix. Keep on ice until use.
  1. Save the following COVIDSeq PCR program on the thermal cycler:
  • Choose the preheat lid option

  • Set the reaction volume to 25 µl

  • 98°C for 3 minutes

  • 35 cycles of:   98°C for 15 seconds 63°C for 5 minutes

  • Hold at 4°C

Procedure:

  1. Label two new PCR plates COV1 and COV2. The plates represent two separate PCR reactions on

each sample and control in the CDNA1 plate.

  1. In a 15 ml tube, combine the following volumes to prepare COVIDSeq PCR 1 Master Mix and

COVIDSeq PCR 2 Master Mix. Multiply each volume by the number of samples. Reagent overage is included to account for small pipetting errors.

ABC
ReagentCOVIDSeq PCR 1 Master Mix (µl)COVIDSeq PCR 2 Master Mix (µl)
IPM1515
CPP14.3N/A
CPP2N/A4.3
Nuclease-free water4.74.7
  1. Add 20 µl COVIDSeq PCR 1 Master Mix to each well of the COV1 plate corresponding to each well of the CDNA1 plate.

  2. Add 5 µl first strand cDNA synthesis from each well of the CDNA1 plate to the corresponding well of the COV1 plate.

  3. Add 20 µl COVIDSeq PCR 2 Master Mix to each well of the COV2 plate corresponding to each well of the CDNA1 plate.

  4. Add 5 µl first strand cDNA synthesis from each well of the CDNA1 plate to the corresponding well of the COV2 plate.

  5. Seal and shake at 1600 rpm for 1 minute.

  6. Centrifuge at 1000 x g for 1 minute.

  7. Place in the preprogrammed thermal cycler and run the COVIDSeq PCR program.

SAFE STOPPING POIN T If you are stopping, seal the plate and store at -25°C to -15°C for up to 3 days.

7.

Tagment PCR Amplicons

Preparation:

  1. Prepare the following consumables: | A | B | C | | --- | --- | --- | | Reagent | Storage | Instructions | | EBLTS | 2°C to 8°C | Bring to room temperature. Vortex thoroughly before use. | | TB1 | -25°C to -15°C | Bring to room temperature. Vortex thoroughly before use. |

  2. If COV1 and COV2 plates were stored frozen, prepare as follows.

a.  Thaw at room temperature.

b. Check seals, and then shake at 1600 rpm for 1 minute.

c. Centrifuge at 1000 x g for 1 minute.

  1. Save the following COVIDSeq TAG program on the thermal cycler:
  • Choose the preheat lid option
  • Set the reaction volume to 50 µl
  • 55°C for 5 minutes
  • Hold at 10°C

Procedure:

  1. Label a new PCR plate TAG1.

  2. Combine COV1 and COV2 as follows.

    a. Transfer 10 µl from each well of the COV1 plate to the corresponding well of the TAG1 plate.

    b. Transfer 10 µl from each well of the COV2 plate to each well of the TAG1 plate containing COV1.

  3. In a 15 ml tube, combine the following volumes to prepare Tagmentation Master Mix. Multiply each volume by the number of samples.

  • TB1 (12 µl)
  • EBLTS (4 µl)
  • Nuclease-free water (20 µl)
  1. Add 30 µl master mix to each well in TAG1 plate.

  2. Seal and shake at 1600 rpm for 1 minute.

  3. Place on the preprogrammed thermal cycler and run the COVIDSeq TAG program.

8.

Post Tagmentation Clean Up:

Preparation:

  1. Prepare the following consumables:
ABC
ReagentStorageInstructions
ST2Room temperatureVortex before use.
TWB2°C to 8°CVortex before use.

Procedure:

  1. Centrifuge the TAG1 plate at 500 x g for 1 minute.

  2. Add 10 µl ST2 to each well of the TAG1 plate.

  3. Seal and shake at 1600 rpm for 1 minute.

  4. Incubate at room temperature for 5 minutes.

  5. Centrifuge at 500 × g for 1 minute.

  6. Place on the magnetic stand and wait until the liquid is clear (~3 minutes).

  7. Inspect for bubbles on the seal. If present, centrifuge at 500 x g for 1 minute, and then place on the magnetic stand (~3 minutes).

  8. Remove and discard all supernatant

  9. Wash beads as follows.

    a. Remove from the magnetic stand.

    b. Add 100 µl TWB to each well.

    c. Seal and shake at 1600 rpm for 1 minute.

    d. Centrifuge 500 × g for 1 minute.

    e. Place on the magnetic stand and wait until the liquid is clear (~3 minutes).

    f. For first wash only, remove and discard all supernatant from each well.

  10. Wash beads a second time. Leave supernatant in plate for second wash to prevent beads from overdrying.

9.

Amplify Tagmented Amplicons:

Preparation

  1. Prepare the following consumables: | A | B | C | | --- | --- | --- | | Reagent | Storage | Instructions | | EPM | -25°C to -15°C | Invert to mix. Keep on ice until use | | Index adapters | -25°C to -15°C | Thaw at room temperature. Vortex to mix, and then centrifuge at 1000 × g for 1 minute. |

  2. Open each prepared index adapter plate seal as follows. Use a new

PCR plate for each different index set.

a. Align a new 96-well PCR plate above the index adapter plate, and then press down to puncture the foil seal.

b. Discard the PCR plate.

  1. Save the following COVIDSeq TAG PCR program on the thermal

cycler:

  • Choose the preheat lid option and set to 100°C

  • Set the reaction volume to 50 µl

  • 72°C for 3 minutes

  • 98°C for 3 minutes

  • 7 cycles of: o 98°C for 20 seconds

              o  60°C for 30 seconds
    
              o  72°C for 1 minute
    
              o  72°C for 3 minutes 
    
  • Hold at 10°C

Procedure:

  1. In a 15 ml tube, combine the following volumes to prepare PCR

Master Mix. Multiply each volume by the number of samples.

  • EPM (24 µl)
  • Nuclease-free water (24 µl)
  1. Vortex PCR Master Mix to mix.

  2. Keep the TAG1 plate on magnetic stand and remove TWB.

  3. Use a 20 µl pipette to remove any remaining TWB.

  4. Remove the TAG1 plate from the magnetic stand.

  5. Add 40 µl PCR Master Mix to each well.

  6. Add 10 µl index adapters to each well of the PCR plate.

  7. Seal and shake at 1600 rpm for 1 minute.

  8. If liquid is visible on the seal, centrifuge at 500 x g for 1 minute.

  9. Inspect to make sure beads are resuspended. To resuspend, set your pipette to 35 µl with the plunger down, and then slowly pipette to mix.

  10. Place on the preprogrammed thermal cycler and run the COVIDSeq TAG PCR program.

10.

Pool and Clean Up Libraries

Preparation:

  1. Prepare the following consumables: | A | B | C | | --- | --- | --- | | Reagent | Storage | Instructions | | ITB or IPB | Room temperature | Vortex thoroughly to mix. | | RSB | 2°C to 8°C | Let stand for 30 minutes to bring to room temperature. Vortex and invert to mix |

2. Prepare 2.5 ml 80% EtOH from absolute EtOH for each tube of pooled libraries.

Procedure for Illumina COVIDSeq Assay (96 Samples):

  1. Centrifuge the TAG1 plate at 500 × g for 1 minute.

  2. Place on the magnetic stand and wait until the

liquid is clear (~3 minutes).

  1. To pool libraries, complete the following steps

appropriate for your kit. Repeat the steps for each additional sample plate.

a. Label a new 1.7 ml tube Pooled IPB. b

b. Transfer 5 µl library from each well of the TAG 1 plate into the Pooled IPB tube.

  1. Vortex the Pooled IPB tubes to mix, and then centrifuge briefly.

  2. Vortex IPB to resuspend.

  3. Add IPB using the resulting volume of Pooled IPB tube volume multiplied by 0.9. For example, for 96 samples, add 432 µl IPB to each tube.

  4. Vortex to mix.

  5. Incubate at room temperature for 5 minutes.

  6. Centrifuge briefly.

  7. Place on the magnetic stand and wait until the liquid is clear (~5 minutes).

  8. Remove and discard all supernatant.

  9. Wash beads as follows.

a. Keep on the magnetic stand and add 1000 µl fresh 80% EtOH to each tube.

b. Wait 30 seconds.

c. Remove and discard all supernatant.

  1. Wash beads a second time.

  2. Use a 20 µl pipette to remove all residual EtOH.

  3. Add 55 µl RSB.

  4. Vortex to mix, and then centrifuge briefly.

  5. Incubate at room temperature for 2 minutes.

  6. Place on the magnetic stand and wait until the liquid is clear (~2 minutes).

  7. Transfer 50 µl supernatant from each Pooled IPB tube to a new microcentrifuge tube.

SAFE STOPPING POINT If you are stopping, cap the tube and store at -25°C to -15°C for up to 30 days.

11.

Quantify and Normalize Libraries

  1. Analyze 2 µl library pool using a Qubit dsDNA HS Assay kit. If libraries are outside the standard range, dilute to 1:10 concentration and analyze again.

  2. Dilute each library pool to a minimum of 30 µl at a normalized concentration 4 nM using RSB according to manufacture specification.

Pool and Dilute Libraries:

After diluting to the starting concentration of 4 nM, libraries are ready to be denatured and diluted

to the final loading concentration according to the specifications of the Illumina sequencing platform.

推荐阅读

Nature Protocols
Protocols IO
Current Protocols
扫码咨询